

November 19, 2025

BSE Limited	Code: 532321	National Stock Exchange of India Limited
P J Towers,		Code: Zyduslife
Dalal Street,		Exchange Plaza, C/1, Block G, Bandra-Kurla
Mumbai-400001		Complex, Bandra (East),
		Mumbai-400051

Re.: <u>Preferential issue of shares by Zydus Foundation, a Section 8-non-profit making company ("ZF"), which is wholly owned subsidiary of Zydus Lifesciences Limited ("the Company"), to Ramanbhai Foundation, a public charitable trust</u>

Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations") read with SEBI Master Circular dated November 11, 2024, and SEBI Circular dated December 31, 2024 ("the SEBI Circulars")

Dear Sir / Madam,

Pursuant to preferential issue and allotment of 4,50,000 equity shares of Rs. 10/- each fully-up of ZF to Ramanbhai Foundation, a public charitable trust, on November 19, 2025, ZF has ceased to be the wholly owned subsidiary of the Company w.e.f. November 19, 2025.

Consequent to the above allotment, the Company shall continue to hold 50,000 equity shares of 7F.

Necessary details as required under regulation 30 read with the SEBI Circulars are provided in **Annexure-"1"**.

Thanking you,

Yours faithfully, For, **Zydus Lifesciences Limited**

Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS 7063

Encl.: As above





Annexure-"1"

Details as prescribed in Para 1.4 of the SEBI Master Circular are provided hereunder:

Sr. No.	Particulars	Responses
a.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year.	Zydus Foundation ("ZF") was incorporated as section 8 Company under the Companies Act, 2013. 100% of equity share capital of ZF was held by Zydus Lifesciences Limited (the "Company"). Details of contribution of ZF to the consolidated Financial Statements of the Company for the Financial Year ended on March 31, 2025, are as under: Income: Zero Net worth: Zero
b.	Date on which the agreement for sale has been entered into.	Not Applicable
C.	The expected date of completion of sale/disposal.	November 19, 2025
d.	Consideration received from such sale/disposal.	Not Applicable
e.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.	Not applicable
f.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".	The equity shares of ZF are subscribed by Ramanbhai Foundation, a public charitable trust at the fair value determined by the SEBI registered valuer. The equity issuance by ZF to the Ramanbhai Foundation has been carried out on an arm's length basis.



g.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not applicable
h.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation / merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable

For, Zydus Lifesciences Limited

Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS 7063